Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical stage neuroscience biotech developing new chemical entities (NCEs) that target the root causes of psychiatric diseases.

Biotech

Why other Big Pharmas could follow Lilly into psychedelics

Industry experts told Fierce that Eli Lilly's $2.8 billion acquisition of AtaiBeckley should give the psychedelics space added momentum.

Will Maddox , Darren Incorvaia Jul 20, 2026 4:00am

Brain and money connected by a thread on a white background

AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program

Aug 25, 2025 9:42am

Fierce Pharma

AbbVie will continue to pursue external innovation for long-term

Jul 31, 2025 11:44am

AbbVie in talks over $1B Gilgamesh buyout: report

Jul 31, 2025 7:48am

Gilgamesh links psychedelic to 94% remission rate in depression

May 27, 2025 11:00am

Introducing Fierce Biotech's 2024 Fierce 15

Aug 5, 2024 6:00am